Both terminal misfolding and polymerisation contribute to disease-relevant phenotypic changes in cell models of alpha-1-antitrypsin deficiency-associated liver disease
Panayiota StylianouiD, Kish R. AdoniiD, Mun Peak Nyon, Adam Cryar, Imran Haq, Jennifer A. DickensiD, Charis‐Patricia Segeritz, Graeme C. Smith, Adriana OrdóñeziD, James A. IrvingiD, David A. LomasiD, Kyra-Mae Leighton, Jessica Beasley, Aleck W.E. Jones, S. Tamir RashidiD, Ludovic VallieriD, Konstantinos ThalassinosiD, Bibek GooptuiD
Abstract
Polymerisation of 1-antitrypsin within hepatocytes is considered central to the pathogenesis of 1-antitrypsin deficiency-associated liver fibrosis, most commonly in homozygotes for the Z (p.Glu342Lys) allele. Polymerisation proceeds via self-association of monomeric intermediate states. In parallel, >50% of synthesised Z 1-antitrypsin is instead recognized as terminally-misfolded and degraded. It is unclear whether this contributes to Z 1-antitrypsin deficiency-associated liver disease. We characterised the relationships between polymer formation, terminal misfolding and their cellular consequences, using label-free proteomics mass spectrometry (MS), light and electron microscopy, and cellular assays. Proteomic analyses of well-established CHO cell models of hepatocyte handling of 1-antitrypsin variants indicated that cellular responses to the Z mutation were surprisingly similar to those seen with the NullHongKong variant (NHK), which can only misfold terminally and cannot polymerise. A minor set of proteins showed increases associated with Z and not NHK 1-antitrypsin expression, consistent with a polymer-specific response, characterized by association with increased organellar organization and vesicle-mediated transport. Conversely, proteostatic and pro-fibrotic integrin-associated pathways increased with the degree of terminal misfolding of the expressed 1-antitrypsin variant. Bioenergetic pathway changes indicated concomitant switching from oxidative to glycolytic metabolism. Cell studies further correlated fibrosis-associated behaviours with terminal misfolding rather than polymerisation. Terminal misfolding, as well as polymerisation behaviour, may therefore be important for pro-fibrotic responses including metabolic reprogramming and senescence in Z 1-antitrypsin deficiency. Molecular therapies may prove most efficacious for associated liver disease if they address terminal misfolding as well as polymerisation.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Development of a small molecule that corrects misfolding and increases secretion of Z α1-antitrypsin
D. Lomas, J. A. Irving, … A. C. Pearce·bioRxiv·Jul 26, 2020
- Molecular insights on the mechanism of α1-antitrypsin condensate formation and maturation
Ignacio Sanchez‐Burgos, Andrés R. Tejedor, … Jorge R. Espinosa·PLoS Computational BiologyPeer-reviewed·Nov 19, 2025
- Resolution of the circulating pathogenic phenotype of alpha-1 antitrypsin deficiency following liver transplantation
Nina Heyer‐Chauhan, Riccardo Ronzoni, … David A. Lomas·Bioscience ReportsPeer-reviewed·Oct 29, 2026
- Z-AAT impairs organelle homeostasis and reduces adaptive response to lipids in alpha-1 antitrypsin deficiency models
Sara Gil-Martín, Nerea Matamala, … Beatriz Martínez–Delgado·bioRxiv·Aug 17, 2026
- CHOP-c-JUN complex plays a critical role in liver proteotoxicity induced by mutant Z alpha-1 antitrypsin.
Sergio Attanasio, Gwladys Gernoux, … Nicola Brunetti‐Pierri·bioRxiv·May 4, 2020
- SAHA increases chaperone expression and reduces Z-alpha-1-antitrypsin polymers in a patient specific iPSC-based liver model for alpha-1-antitrypsin deficiency
Nina Graffmann, Rabea Hokamp, … James Adjaye·Stem Cell Research & TherapyPeer-reviewed·Oct 27, 2026